GUSKA
GUSKA provides targeted cancer therapies using programmable synthetic RNA oncolytic viruses. The platform uses synthetic RNA backbones to create oncolytic viruses that selectively infect tumor cells, enhance immune response, and reduce harm to normal tissue, with AI tools to guide design and optimization. Category: B2B biotech platform; customers include research institutions and pharma companies. The approach aims to scale through partnerships and clinical development for solid tumors.
GUSKA
GUSKA provides targeted cancer therapies using programmable synthetic RNA oncolytic viruses. The platform uses synthetic RNA backbones to create oncolytic viruses that selectively infect tumor cells, enhance immune response, and reduce harm to normal tissue, with AI tools to guide design and optimization. Category: B2B biotech platform; customers include research institutions and pharma companies. The approach aims to scale through partnerships and clinical development for solid tumors.